France Biotech Presents The Results Of Its Twelfth Annual Survey, « panorama Of The Life Sciences® » - Yahoo Finance

December 18, 2014

Our SMEs have a very high level of technical expertise and efficiency, allowing them to quickly bring numerous projects to advanced stages of development. This wealth has convinced stock market investors to invest in our industry, a unique phenomenon in Europe that rewards SMEs founded in the 2000s. These success stories belong to outstanding entrepreneurs and their venture capital investors, and are a sign of both maturity and promising growth potential. However, our youngest companies are struggling; venture capital investors are fewer and have less power than they used to. The entire funding chain is fragile, and the serious lack of incentives to channel French household savings toward innovative companies cant be fully compensated by the efforts of Bpifrance (a public investment bank), said Pierre-Olivier Goineau, President of France Biotech. In order for our innovations to stir economic growth and job creation, some obstacles blocking our way ought to be removed. These include excessive paperwork and administrative tasks when dealing with multiples layers of academic institutions; delays in applying to CIR (the Research Tax Credit, a French tax incentive mechanism to support investments in SMEs); a lack of understanding of the specificities of our industry from the ANSM (the French Agency for the Safety of site web Health Products, whose task is to assess the risks posed by new health products); scarcity of the dialogue with the public health authorities; suppression of the Precautionary Principle that generates fears, said M. Goineau.

Go Back